European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
Lee, G.A. (Division of Applied Technology for Clinical Care. Florence Nightingale Faculty of Nursing. Midwifery & Palliative Care. King's College London)
Aktaa, S. (Department of Cardiology. Leeds Teaching Hospitals NHS Trust)
Baker, E. (Division of Applied Technology for Clinical Care. Florence Nightingale Faculty of Nursing. Midwifery & Palliative Care. King's College London)
Gale, C.P. (Department of Cardiology. Leeds Teaching Hospitals NHS Trust)
Yaseen, I.F. (Scientific Council of Cardiology. Iraqi Board for Medical Specializations)
Gulati, G. (Oslo University Hospital (Oslo, Noruega))
Asteggiano, R. (LARC (Laboratorio Analisi e Ricerca Clinica))
Szmit, S. (Institute of Hematology and Transfusion Medicine)
Cohen-Solal, A. (Cardiology Department. Hôpitaux de Paris. Hôpital Lariboisière 2 Rue Ambroise Paré)
Abdin, A. (Department of Internal Medicine III. Cardiology. Angiology. Intensive Care Medicine. Saarland University Medical Center)
Jurczak, W. (MSC National Research Institute of Oncology)
Garrido, Pilar (Jefe Servicio Oncología Médica. Hospital Ramón y Cajal)
Sverdlov, A.L. (Newcastle Centre of Excellence in Cardio-Oncology. Calvary Mater Newcastle. Hunter Medical Research Institute. John Hunter Hospital. University of Newcastle)
Tocchetti, C.G. (Cardio-Oncology Unit. Department of Translational Medical Sciences (DISMET). Center for Basic and Clinical Immunology Research (CISI). Interdepartmental Center for Clinical and Translational Research (CIRCET). Interdepartmental Hypertension Research Center (CIRIAPA). Federico II University)
Barac, A. (Cardio-oncology Program. MedStar Heart and Vascular Institute)
Parrini, I. (Department of Cardiology. Mauriziano Hospital)
Zamorano, P. (Hospital Universitario Ramón y Cajal (Madrid))
Iakobishvili, Z. (Faculty of Health Sciences. Ben Gurion University of the Negev)
Pudil, R. (University Hospital Hradec Králové. Sokolská)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Kirby, A.M. (Royal Marsden NHS Trust. Institute of Cancer Research)
Blaes, A.H. (Division of Hematology/Oncology/Transplantation. University of Minnesota)
Farmakis, D. (University of Cyprus Medical School)
Curigliano, Giuseppe (IRCCS. European Institute of Oncology)
Stephens, R. (Patient Advocate)
Lyon, A.R. (National Heart and Lung Institute. Imperial College London. Cardio-Oncology Service. Royal Brompton Hospital)
Lopez-Fernandez, T. (Hospital Universitario La Paz. Instituto de Investigación IdiPAZ. Servicio de Cardiología)

Data:	2023
Resum:	Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Quality indicators ; Cardio-oncology ; Assessment ; Treatment ; Cancer therapy-related cardiovascular toxicity ; Outcomes
Publicat a:	European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9 Núm. 1 (january 2023) , p. 1-7, ISSN 2058-1742

DOI: 10.1093/ehjqcco/qcac070
PMID: 36316010

7 p, 264.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats